CYTK has been in the news 429% more than usual
Sep 30, 2025, 10:32 PM
3.49%
What does CYTK do
Cytokinetics, a South San Francisco-based biopharmaceutical company, develops muscle activators and inhibitors for diseases affecting muscle performance, with key drug candidates including aficamten and omecamtiv mecarbil. Founded in 2004, it employs 423 people and specializes in cardiac muscle function.
CYTK has been in the news recently: Cytokinetics is facing multiple class action lawsuits related to its stock purchases between December 27, 2023, and May 6, 2025, due to allegations of misleading statements regarding FDA approval. Additionally, the Schall Law Firm is investigating potential securities law violations after the company's shares fell more than 12% following delays in drug approval.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.